bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but you should cut through the technical jargon to understand what is happening under the hood. Here is the breakdown in plain English.

1. What does this company do?

BioAffinity is a diagnostics company. Think of them as developers of an "early warning system" for lung diseases. Their main product is CyPath® Lung. Instead of an invasive, expensive, and risky biopsy, their test uses flow cytometry to analyze a patient's phlegm sample. It looks for signs of lung cancer under a microscope.

They use proprietary artificial intelligence to analyze these samples. In clinical trials for patients with small lung nodules, the test showed 92% sensitivity and 87% specificity. It correctly identified cancer or the lack of it about 88% of the time. The goal is to help doctors avoid unnecessary surgeries for patients who do not have cancer.

2. What is the financial situation?

As of June 2026, the company is raising money through a public offering of stock priced at $0.80 per share.

The hard truth: The company is not profitable and has a history of significant losses. As of March 31, 2026, they reported a total loss of $72.2 million and $3.1 million in cash. They have been very clear: they are currently a "going concern." This means their auditors doubt the company can stay in business. Their current cash is not enough to fund operations for the next 12 months without raising more money.

3. What are the big risks?

Investing in a company at this stage is high-stakes. Beyond the cash shortage, here is what you should watch:

• The "David vs. Goliath" Problem: The biotech world is crowded with massive, well-funded companies. BioAffinity is a small player. If a larger competitor creates a cheaper or faster test, bioAffinity could be pushed out of the market.
• Reliance on Others: They do not manufacture their own test kits. They rely on third-party suppliers. If those suppliers have production delays or price increases, bioAffinity’s business could stall. They also rely on outside labs to process samples, meaning they have less control over their research.
• The "Key Person" Risk: The company depends on a small group of top executives. If these leaders leave, the company may struggle to find replacements with the experience needed to navigate FDA regulations.
• Legal and Privacy Headaches: They handle sensitive health data and must follow strict privacy laws like HIPAA. A data breach or failure to follow federal regulations could lead to massive fines and damage their reputation.
• Liability: If a test misses a cancer diagnosis or leads to unnecessary surgery, the company could face lawsuits. While they carry insurance, it might not cover a major legal claim.

4. The Bottom Line

The company trades on the Nasdaq under the symbol BIAF. They are showing progress, but they are a small player in a tough industry. This is a speculative investment. It is only for those who understand the company is fighting for survival. Any setback in their testing, regulations, or management could be devastating.

How to move forward: If you are still interested, don't just take this summary at face value. Before you put any money down, take 15 minutes to look at their official "Prospectus" on the SEC’s EDGAR website. Look specifically for the "Risk Factors" section—it’s the most honest part of the document and will give you the full picture of what could go wrong.

Disclaimer: I am an AI, not a financial advisor. This is a high-risk, speculative investment. Never invest money you cannot afford to lose.